From the Past to the Present

Insurer Coverage Frameworks for Next-Generation Tumor Sequencing

Julia R. Trosman*, Christine B. Weldon, William J. Gradishar, Al B Benson III, Massimo Cristofanilli, Allison W. Kurian, James M. Ford, Alan Balch, John Watkins, Kathryn A. Phillips

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Next-generation sequencing promises major advancements in precision medicine but faces considerable challenges with insurance coverage. These challenges are especially important to address in oncology in which next-generation tumor sequencing (NGTS) holds a particular promise, guiding the use of life-saving or life-prolonging therapies. Payers’ coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions. Some experts have called for the adaptation of the coverage framework to make it better equipped for assessing NGTS. Medicare's recent decision to cover NGTS makes this topic particularly urgent to examine. In this article, we discussed the previously proposed approaches for adaptation of the NGTS coverage framework, highlighted their innovations, and outlined remaining gaps in their ability to assess the features of NGTS. We then compared the three approaches with Medicare's national coverage determination for NGTS and discussed its implications for US private payers as well as for other technologies and clinical areas. We focused on US payers because analyses of coverage approaches and policies in the large and complex US health care system may inform similar efforts in other countries. We concluded that further adaptation of the coverage framework will facilitate a better suited assessment of NGTS and future genomics innovations.

Original languageEnglish (US)
Pages (from-to)1062-1068
Number of pages7
JournalValue in Health
Volume21
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Insurance Carriers
Neoplasms
Medicare
Technology
Precision Medicine
Aptitude
Insurance Coverage
Genomics
Decision Making
Delivery of Health Care

Keywords

  • insurance coverage
  • next-generation sequencing
  • precision medicine
  • precision oncology
  • reimbursement
  • tumor sequencing

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Trosman, Julia R. ; Weldon, Christine B. ; Gradishar, William J. ; Benson III, Al B ; Cristofanilli, Massimo ; Kurian, Allison W. ; Ford, James M. ; Balch, Alan ; Watkins, John ; Phillips, Kathryn A. / From the Past to the Present : Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. In: Value in Health. 2018 ; Vol. 21, No. 9. pp. 1062-1068.
@article{82a45538ebe04f35b213e59d89168e22,
title = "From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing",
abstract = "Next-generation sequencing promises major advancements in precision medicine but faces considerable challenges with insurance coverage. These challenges are especially important to address in oncology in which next-generation tumor sequencing (NGTS) holds a particular promise, guiding the use of life-saving or life-prolonging therapies. Payers’ coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions. Some experts have called for the adaptation of the coverage framework to make it better equipped for assessing NGTS. Medicare's recent decision to cover NGTS makes this topic particularly urgent to examine. In this article, we discussed the previously proposed approaches for adaptation of the NGTS coverage framework, highlighted their innovations, and outlined remaining gaps in their ability to assess the features of NGTS. We then compared the three approaches with Medicare's national coverage determination for NGTS and discussed its implications for US private payers as well as for other technologies and clinical areas. We focused on US payers because analyses of coverage approaches and policies in the large and complex US health care system may inform similar efforts in other countries. We concluded that further adaptation of the coverage framework will facilitate a better suited assessment of NGTS and future genomics innovations.",
keywords = "insurance coverage, next-generation sequencing, precision medicine, precision oncology, reimbursement, tumor sequencing",
author = "Trosman, {Julia R.} and Weldon, {Christine B.} and Gradishar, {William J.} and {Benson III}, {Al B} and Massimo Cristofanilli and Kurian, {Allison W.} and Ford, {James M.} and Alan Balch and John Watkins and Phillips, {Kathryn A.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jval.2018.06.011",
language = "English (US)",
volume = "21",
pages = "1062--1068",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "9",

}

From the Past to the Present : Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. / Trosman, Julia R.; Weldon, Christine B.; Gradishar, William J.; Benson III, Al B; Cristofanilli, Massimo; Kurian, Allison W.; Ford, James M.; Balch, Alan; Watkins, John; Phillips, Kathryn A.

In: Value in Health, Vol. 21, No. 9, 01.09.2018, p. 1062-1068.

Research output: Contribution to journalArticle

TY - JOUR

T1 - From the Past to the Present

T2 - Insurer Coverage Frameworks for Next-Generation Tumor Sequencing

AU - Trosman, Julia R.

AU - Weldon, Christine B.

AU - Gradishar, William J.

AU - Benson III, Al B

AU - Cristofanilli, Massimo

AU - Kurian, Allison W.

AU - Ford, James M.

AU - Balch, Alan

AU - Watkins, John

AU - Phillips, Kathryn A.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Next-generation sequencing promises major advancements in precision medicine but faces considerable challenges with insurance coverage. These challenges are especially important to address in oncology in which next-generation tumor sequencing (NGTS) holds a particular promise, guiding the use of life-saving or life-prolonging therapies. Payers’ coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions. Some experts have called for the adaptation of the coverage framework to make it better equipped for assessing NGTS. Medicare's recent decision to cover NGTS makes this topic particularly urgent to examine. In this article, we discussed the previously proposed approaches for adaptation of the NGTS coverage framework, highlighted their innovations, and outlined remaining gaps in their ability to assess the features of NGTS. We then compared the three approaches with Medicare's national coverage determination for NGTS and discussed its implications for US private payers as well as for other technologies and clinical areas. We focused on US payers because analyses of coverage approaches and policies in the large and complex US health care system may inform similar efforts in other countries. We concluded that further adaptation of the coverage framework will facilitate a better suited assessment of NGTS and future genomics innovations.

AB - Next-generation sequencing promises major advancements in precision medicine but faces considerable challenges with insurance coverage. These challenges are especially important to address in oncology in which next-generation tumor sequencing (NGTS) holds a particular promise, guiding the use of life-saving or life-prolonging therapies. Payers’ coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions. Some experts have called for the adaptation of the coverage framework to make it better equipped for assessing NGTS. Medicare's recent decision to cover NGTS makes this topic particularly urgent to examine. In this article, we discussed the previously proposed approaches for adaptation of the NGTS coverage framework, highlighted their innovations, and outlined remaining gaps in their ability to assess the features of NGTS. We then compared the three approaches with Medicare's national coverage determination for NGTS and discussed its implications for US private payers as well as for other technologies and clinical areas. We focused on US payers because analyses of coverage approaches and policies in the large and complex US health care system may inform similar efforts in other countries. We concluded that further adaptation of the coverage framework will facilitate a better suited assessment of NGTS and future genomics innovations.

KW - insurance coverage

KW - next-generation sequencing

KW - precision medicine

KW - precision oncology

KW - reimbursement

KW - tumor sequencing

UR - http://www.scopus.com/inward/record.url?scp=85050874455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050874455&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2018.06.011

DO - 10.1016/j.jval.2018.06.011

M3 - Article

VL - 21

SP - 1062

EP - 1068

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 9

ER -